Benjamin Hohl - 27 Dec 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Issuer symbol
ELVN
Transactions as of
27 Dec 2024
Net transactions value
-$83,934
Form type
4
Filing time
31 Dec 2024, 17:18:12 UTC
Previous filing
07 Jan 2025
Next filing
29 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $8,308 +3,350 $2.48 3,350 27 Dec 2024 Direct F1
transaction ELVN Common Stock Sale $74,219 -3,350 -100% $22.15 0 27 Dec 2024 Direct F1, F2
transaction ELVN Common Stock Options Exercise $2,232 +900 $2.48 900 30 Dec 2024 Direct F1
transaction ELVN Common Stock Sale $20,255 -900 -100% $22.51 0 30 Dec 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -3,350 -2% $0.000000 165,206 27 Dec 2024 Common Stock 3,350 $2.48 Direct F1, F4
transaction ELVN Stock Option (right to buy) Options Exercise $0 -900 -0.54% $0.000000 164,306 30 Dec 2024 Common Stock 900 $2.48 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $21.58 to $22.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $22.50 to $22.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.